| SKU:K1359 | M. Wt:295.29 | ||
| Formula:C12H15N5O3.H2O | Solubility:No | ||
| Purity:>99% | Storage:2 years at -20 degrees centigrade | ||
| CAS No.:209216-23-9 | Synonyms:Baraclude | ||
| Chemical NameN/A | |||
| 供货周期： | 一周 |
| 品牌： | |
| 规格： | 2mg |
| 货号： | K1359 |
| CAS号： | 209216-23-9 |
| SKU:K1359 | M. Wt:295.29 | ||
| Formula:C12H15N5O3.H2O | Solubility:No | ||
| Purity:>99% | Storage:2 years at -20 degrees centigrade | ||
| CAS No.:209216-23-9 | Synonyms:Baraclude | ||
| Chemical NameN/A | |||
| Description | Entecavir hydrate | |||||
|---|---|---|---|---|---|---|
| Targets | N/A | |||||
| IC50 | N/A | |||||
| In vitro | Entecavir is an oral antiviral drug with selective activity against hepatitis B virus (HBV). Entecavir (ETV) exhibits potent antiviral activity in patients chronically infected with wild-type or lamivudine (3TC)-resistant (3TC(r)) hepatitis B virus (HBV). | |||||
| In vivo | All doses of entecavir (0.05 mg, 0.1 mg, 0.5 mg, and 1.0 mg) showed a pronounced suppression of replication of the HBV. Entecavir reduced HBV DNA by an additional 0.97 log(10) at the 0.1-mg/day dose and an additional 1.28 log(10) at the 0.5-mg/day dose. In this 28-day study of entecavir a pronounced decrease of HBV DNA was observed and there were no significant side effects in entecavir patients in comparison with placebo-treated patients. | |||||
| Clinical Trials | N/A | |||||
| Features | N/A | |||||
相关产品
重组人肌球蛋白轻链2(Recombinant Human MYL2)
重组大鼠抵抗素(Rat Resistin)
大鼠酸性磷酸酶(ACP)ELISA Kit
大鼠胆囊收缩素/缩胆囊素八肽(CCK-8)ELISA Kit
人瘦素(LEP)ELISA Kit
重组人半乳糖凝集素16/LGALS16 Human
重组人半乳糖凝集素8/Human LGALS8 His
重组人半乳糖凝集素3/Human LGALS3 His
重组人卵泡抑素/Human FST His
重组人β防御素118/DEFB118 Human
重组人心肌营养素1/CTF1 Human
特级新生牛血清（无支原体）
超级新生牛血清（无支原体）
优级胎牛血清（无支原体）
特级新生牛血清（无噬菌体低内毒素）
工商信息
信息已认证
联系方式
详细地址
关注
拨打电话
留言咨询
